New developments in the management of hepatitis C virus infection: focus on boceprevir

References

• HeathcoteEJAntiviral therapy: chronic hepatitis CJ Viral Hepat200714Suppl 1S82S88
   PubMed Web of Science ®Google Scholar
• KronenbergerBZeuzemSNew developments in HCV therapyJ Viral Hepat201219Suppl 1S48S51
   Web of Science ®Google Scholar
• CuevasJMGonzález-CandelasFMoyaASanjuanREffect of ribavirin on the mutation rate and spectrum of hepatitis C virus in vivoJ Virol200983115760576419321623
   PubMed Web of Science ®Google Scholar
• TamRCPaiBBardJRibavirin polarizes human T cell responses towards a Type 1 cytokine profileJ Hepatol199930337638210190717
   PubMed Web of Science ®Google Scholar
• MaylinSMartinot-PeignouxMMoucariREradication of hepatitis C virus in patients successfully treated for chronic hepatitis CGastroenterology2008135382182918593587
   PubMed Web of Science ®Google Scholar
• CardosoACMoucariRFigueiredo-MendesCImpact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosisJ Hepatol201052565265720346533
   PubMed Web of Science ®Google Scholar
• AsselahTEstrabaudEBiecheIHepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirinLiver Int20103091259126920633102
   PubMed Web of Science ®Google Scholar
• GeDFellayJThompsonAJGenetic variation in IL28B predicts hepatitis C treatment-induced viral clearanceNature2009461726239940119684573
   PubMed Web of Science ®Google Scholar
• Boceprevir, EMA Label http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002332/WC500109789.pdfAccessed May 15, 2012
   Google Scholar
• Boceprevir, FDA Label http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202258lbl.pdfAccessed May 15, 2012
   Google Scholar
• LiXDSunLSethRBPinedaGChenZJHepatitis C virus protease NS3/4A cleaves mitochondrial antiviral signaling protein off the mitochondria to evade innate immunityProc Natl Acad Sci U S A200510249177171772216301520
   PubMed Web of Science ®Google Scholar
• GelmanMAGlennJSMixing the right hepatitis C inhibitor cocktailTrends Mol Med20111713446
   Web of Science ®Google Scholar
• MalcolmBALiuRLahserFSCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cellsAntimicrob Agents Chemother20065031013102016495264
   PubMed Web of Science ®Google Scholar
• BaconBRGordonSCLawitzEBoceprevir for previously treated chronic HCV genotype 1 infectionN Engl J Med2011364131207121721449784
   PubMed Web of Science ®Google Scholar
• PoordadFMcConeJBaconBRBoceprevir for untreated chronic HCV genotype 1 infectionN England J Med2011364131195120621449783
   PubMed Web of Science ®Google Scholar
• MangiaAMottolaLTreatment of non-genotype 1 hepatitis C virus patientsCurr Gastroenterol Rep2012141879322113745
   PubMedGoogle Scholar
• SchiffEPoordadEJacobsonIBoceprevir (B) combination therapy in null responders (NR): response dependent on interferon responsivenessJ Hepatol200848Suppl 2S46
   Web of Science ®Google Scholar
• KwoPLawitzEMcConeJHCV SPRINT-1 final results: SVR from a phase 2 study of boceprevir plus pegintron (Peg-IFN alpha-2b)/RBV in treatment-naive subjects with genotype 1 chronic hepatitis CJ Hepatol200950Suppl 1S4
   Web of Science ®Google Scholar
• BaconBRGordonSCLawitzERESPOND-2 final results: high sustained virologic response among genotype 1 previous nonresponders and relapsers to peginterferon/ribavirin when re-treated with boceprevir plus PEGINTRON (Peginterferon alfa-2b)/ribavirinHepatology201052Suppl 1S430A
   Google Scholar
• KwoPYLawitzEJMcConeJEfficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trialLancet2010376974270571620692693
   PubMed Web of Science ®Google Scholar
• BronowickiJMcConeJBaconBRResponse-guided therapy (RGT) with boceprevir (BOC) + peginterferon alfa-2b/ribavirin (P/R) for treatment-naïve patients with hepatitis C virus (HCV) genotype (G) 1 was Similar to a 48-Wk fixed-duration regimen with BOC + P/R in SPRINT-2Hepatology201052Suppl 1S881A
   Google Scholar
• LuLPilot-MatiasTJStewartKDMutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitroAntimicrob Agents Chemother20044862260226615155230
   PubMed Web of Science ®Google Scholar
• TrozziCBartholomewLCeccacciAIn vitro selection and characterization of hepatitis C virus serine protease variants resistant to an active-site peptide inhibitorJ Virol20037763669367912610142
   PubMed Web of Science ®Google Scholar
• LinCLinKLuongYPIn vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanismsJ Biol Chem200427917175081751414766754
   PubMed Web of Science ®Google Scholar
• MoHLuLPilot-MatiasTMutations conferring resistance to a hepatitis C virus (HCV) RNA-dependent RNA polymerase inhibitor alone or in combination with an HCV serine protease inhibitor in vitroAntimicrob Agents Chemother200549104305431416189112
   PubMed Web of Science ®Google Scholar
• YiMTongXSkeltonAMutations conferring resistance to SCH6, a novel hepatitis C virus NS3/4A protease inhibitor: Reduced RNA replication fitness and partial rescue by second-site mutationsJ Biol Chem2005281128205821516352601
   PubMed Web of Science ®Google Scholar
• SeiwertSHongJLimSTanHKossenKBlattL [abstract]Rev Antiviral Ther2007156
   Google Scholar
• ZhouYMuhUHanzelkaBLPhenotypic and structural analyses of hepatitis C virus NS3 protease arg155 variants: sensitivity to telaprevir (VX-950) and interferon alphaJ Biol Chem200728231226192262817556358
   PubMed Web of Science ®Google Scholar
• SusserSForestierNWelkerMWDetection of resistant variants in the hepatitis C virus ns3 protease gene by clonal sequencing at long-term follow-up in patients treated with boceprevirJ Hepatol200950Suppl 1S12
   Google Scholar
• McHutchisonJGEversonGTGordonSCTelaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infectionN Engl J Med2009360181827183819403902
   PubMed Web of Science ®Google Scholar
• HezodeCForestierNDusheikoGTelaprevir and peginterferon with or without ribavirin for chronic HCV infectionN Engl J Med2009360181839185019403903
   PubMed Web of Science ®Google Scholar
• SarrazinCKiefferTLBartelsDDynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevirGastroenterology200713251767177717484874
   PubMed Web of Science ®Google Scholar
• DomingoEGenetic variation and quasi-speciesCurr Opin Genet Dev19922161631633428
   PubMed Web of Science ®Google Scholar
• NájeraIHolguínAQuinones-MateuMEPol gene quasispecies of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undergoing no drug therapyJ Virol199569123317983713
   PubMed Web of Science ®Google Scholar
• SusserSWelschCWangYCharacterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patientsHepatology20095061709171819787809
   PubMed Web of Science ®Google Scholar
• HalfonPLocarniniSHepatitis C virus resistance to protease inhibitorsJ Hepatol201155119220621284949
   PubMed Web of Science ®Google Scholar
• SusserSForestierNVermehrenJDecline of detectable resistance mutations within the NS3 protease quasispecies during long-term follow-up after treatment with telaprevirJ Hepatol201052Suppl 1S300
   Web of Science ®Google Scholar
• VermehrenJSusserSLangeCMMutations selected in the hepatitis C virus NS3 protease domain during sequential treatment with boceprevir with and without pegylated interferon alfa-2bJ Viral Hepat201219212012722239501
   PubMed Web of Science ®Google Scholar
• VierlingJMRalstonRLawitzEJLong-term outcomes following combination treatment with boceprevir plus pegintron/ribavirin (P/R) in patients with chronic hepatitis C, genotype 1 (CHC-G1)J Hepatol201052Suppl 1S470S471
   Web of Science ®Google Scholar
• SimmondsPGenetic diversity and evolution of hepatitis C virus – 15 years onJ Gen Virol200485113173318815483230
   PubMed Web of Science ®Google Scholar
• CondraJHSchleifWABlahyOMIn vivo emergence of HIV-1 variants resistant to multiple protease inhibitorsNature199537465225695717700387
   PubMed Web of Science ®Google Scholar
• López-LabradorFXMoyaAGonzález-CandelasFMapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolatesAntivir Ther200813448149418672527
   PubMed Web of Science ®Google Scholar
• SarrazinCZeuzemSResistance to direct antiviral agents in patients with hepatitis C virus infectionGastroenterology2010138244746220006612
   PubMed Web of Science ®Google Scholar
• KuntzenTTimmJBericalANaturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patientsHepatology20084861769177819026009
   PubMed Web of Science ®Google Scholar
• GaudieriSRauchAPfafferottKHepatitis C virus drug resistance and immune-driven adaptations: Relevance to new antiviral therapyHepatology20094941069108219263475
   PubMed Web of Science ®Google Scholar
• KiefferTLSarrazinCMillerJSTelaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patientsHepatology200746363163917680654
   PubMed Web of Science ®Google Scholar
• RongLDahariHRibeiroRMPerelsonASRapid emergence of protease inhibitor resistance in hepatitis C virusSci Transl Med20102303032
   Web of Science ®Google Scholar
• McHutchisonJGMannsMPMuirAJTelaprevir for previously treated chronic HCV infectionN Engl J Med2010362141292130320375406
   PubMed Web of Science ®Google Scholar
• KlibanovOMVickerySBOlinJLSmithLSWilliamsSHBoceprevir: a novel NS3/4 protease inhibitor for the treatment of hepatitis CPharmacotherapy201232217319022392426
   PubMed Web of Science ®Google Scholar
• HezodeCBoceprevir and telaprevir for the treatment of chronic hepatitis C: safety management in clinical practiceLiver Int201232Suppl 1S32S38
   Web of Science ®Google Scholar
• BaconBRKhalidOTriple therapy with boceprevir for HCV genotype 1 infection: Phase III results in relapsers and nonrespondersLiver Int201232Suppl 1S51S53
   Web of Science ®Google Scholar
• RamachandranPFraserAAgarwalKUK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patientsAliment Pharmacol and Ther201235664766222296568
   PubMed Web of Science ®Google Scholar
• ReddyKRBrunoSRossaroLPredictors of sustained virologic response among treatment-naive patients with hepatitis C virus genotype 1 when treated with boceprevir (BOC) plus peginterferon alfa-2b/ribavirin (Pr)J Hepatol201154Suppl 1S190S190
   Web of Science ®Google Scholar
• FosterGRZeuzemSAndreonePSubanalyses of the telaprevir lead-in arm in the realize study: response at week 4 is not a substitute for prior null response categorizationJ Hepatol201154Suppl 1S3S4
   Web of Science ®Google Scholar
• LokASGardinerDFLawitzEPreliminary study of two antiviral agents for hepatitis C genotype 1N Engl J Med2012366321622422256805
   PubMed Web of Science ®Google Scholar
• JacobsonIMPawlotskyJ-MAfdhalNHA practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis CJ Viral Hepat201219Suppl 2S1S26
   PubMed Web of Science ®Google Scholar
• ThomasDLBartlettJGPetersMGShermanKESulkowskiMSPhamPAProvisional guidance on the use of hepatitis C virus protease inhibitors for treatment of hepatitis C in HIV-infected personsClin Infect Dis201254797998322173234
   PubMed Web of Science ®Google Scholar
• NairLGSannigrahiMBogenSP4 capped amides and lactams as HCV NS3 protease inhibitors with improved potency and DMPK profileBioorg Med Chem Lett20102056757020004570
   PubMed Web of Science ®Google Scholar
• BerenguerMLópez-LabradorFXBoceprevir in the treatment of chronic hepatitis C virus infectionVirus Adaptation and Treatment20113717
   Google Scholar